Method and system for treatment of cardiovascular disorders

Patent metadata

Field	Value
Publication number	US-9327000-B2
Application number	US-201514711492-A
Country	US
Kind code	B2
Filing date	May 13, 2015
Priority date	Jan 18, 2006
Publication date	May 3, 2016
Grant date	May 3, 2016

Abstract

Methods for treating a cardiovascular disorder comprising administration of one or more extracellular matrix (ECM) based compositions directly to damaged or diseased cardiovascular tissue associated with the cardiovascular disorder, and provision of ventricular assistance.

First claim

What is claimed is:

1. A method of treating a cardiovascular disorder in a subject, comprising:
providing an extracellular matrix (ECM) composition comprising acellular ECM, said acellular ECM comprising endogenous proteoglycans, transforming growth factor-β (TGF-β) and vascular endothelial growth factor (VEGF), said ECM composition further comprising an added growth factor selected from the group consisting of fibroblast growth factor-2 (FGF-2), basic fibroblast growth factor (bFGF), transforming growth factor-alpha (TGF-α), transforming growth factor-beta (TGF-β), and vascular epithelial growth factor (VEGF), wherein, when said ECM composition is administered to damaged cardiovascular tissue, said growth factor augmented ECM composition induces myofibroblast and stem cell migration, and differentiation of said stem cells into cardiomyocytes;
providing a mechanical circulatory support (MSC) device that is configured to support ventricular function of a mammalian heart when connected thereto;
connecting said MSC device to said subject's circulatory system;
administering said ECM composition proximate damaged cardiovascular tissue of said subject's heart, wherein said ECM composition induces neovascularization and bioremodeling of said subject's damaged cardiovascular tissue; and
providing support of ventricular function of said subject's heart with said MSC device.

2. The method of claim 1 , wherein said ECM comprises ECM from mammalian tissue selected from the group consisting of small intestine submucosa, urinary bladder submucosa, stomach submucosa, placental tissue, mesothelial tissue, ornomentum tissue and kidney tissue.

3. The method of claim 1 , wherein said ECM composition is administered directly to said subject's damaged cardiovascular tissue.

Assignees

• Cormatrix Cardiovascular Inc

Inventors

• Matheny Robert G

Classifications

• A61K35/12 Primary

  Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00) · CPC title

• A61L2300/434

  of enzymes · CPC title

• A61L27/3633

  Extracellular matrix [ECM] · CPC title

• A61L27/367

  Muscle tissue, e.g. sphincter · CPC title

• A61K38/1808

  Epidermal growth factor [EGF] urogastrone · CPC title